Cell Mogrify Ltd, a Cambridge, England, UK-based developer of cell therapies, held the second close on its seed funding, now totalling $3.7m.
The round was led by existing investor Ahren Innovation Capital (Ahren), with 24Haymarket and Dr Disley also investing.
Led by newly appointed Darrin M Disley, PhD, DSc, OBE, as CEO, a renowned scientist, entrepreneur, angel investor, the company will use the funding to market novel IP and cell types generated using its proprietary direct cellular conversion platform, which will power the development and manufacture of lifesaving cell therapies across all therapeutic areas.
Mogrify will commercialize its cellular trans differentiation platform via IP licensing, product development, internal and partnered drug development.
The company was founded by CSO Professor Julian Gough (LMB, Cambridge, UK), Professor Jose Polo (Monash University, Melbourne, AU), and Assistant Professor Owen Rackham (Duke-NUS, Singapore), and is chaired by Professor Steve Jackson, FRS, Ahren Science Partner, originator of Olaparib/Lynparza, and University of Cambridge Professor of Biology.